LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced its cash position for the fourth quarter of 2016. As of December 31, 2016, cash and cash equivalents were EUR €45.6 million (USD $48.1 million).
